Search - tctmd.com

Displaying 1 - 20 of 419

Sort: Relevancy | Date

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

News Daily News

Risk Calculators Miss Many Patients Who Present With First MI

Michael O'Riordan

November 21, 2025

News Conference News AHA 2025

Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia

Michael O'Riordan

November 14, 2025

News Conference News AHA 2025

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

Michael O'Riordan

November 10, 2025

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

News Daily News

High Aerobic Fitness Linked to Less Chronic Disease in Later Life

Michael O'Riordan

October 10, 2025

News Daily News

Risk Factors Present in Nearly All Patients Who Develop CVD

Michael O'Riordan

October 02, 2025

News Daily News

CVD Still the Leading Cause of Death and Disease Globally

Michael O'Riordan

September 24, 2025

News Daily News

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

Michael O'Riordan

September 18, 2025

News Conference News ESC 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Michael O'Riordan

September 10, 2025

News Daily News

Evolocumab Gains Expanded Indication for Primary Prevention

Michael O'Riordan

August 26, 2025

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

News Daily News

PREVENT Risk Calculator’s Accuracy Varies by Healthcare System, Patient Factors

Michael O'Riordan

July 18, 2025

News Daily News

Heart Disease Deaths Decline Over Last 50 Years, but Not Across the Board

Michael O'Riordan

June 25, 2025

News Daily News

Majority of US Adults Have High Long-term Risk of CVD: NHANES

Michael O'Riordan

June 13, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Daily News

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Michael O'Riordan

May 07, 2025

News Daily News

HDL Cholesterol Levels May Sway Statin Decisions in Primary Prevention

Michael O'Riordan

May 02, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

Advertisement

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Risk Calculators Miss Many Patients Who Present With First MI

Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

High Aerobic Fitness Linked to Less Chronic Disease in Later Life

Risk Factors Present in Nearly All Patients Who Develop CVD

CVD Still the Leading Cause of Death and Disease Globally

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Evolocumab Gains Expanded Indication for Primary Prevention

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

PREVENT Risk Calculator’s Accuracy Varies by Healthcare System, Patient Factors

Heart Disease Deaths Decline Over Last 50 Years, but Not Across the Board

Majority of US Adults Have High Long-term Risk of CVD: NHANES

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

HDL Cholesterol Levels May Sway Statin Decisions in Primary Prevention

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content